Genmab — August 2018

[JørgenVarnæs]

Jamen vi har jo forskellige forståelser af situationen - hvis der virkelig er hold I knock-your-socks-off, så kan jeg ikke se begrundelsen for at investere i kompetencer, som hverken giver ekstraordinære afkast, basis for udvikling af kernekompetencer, eller danner nogen form for konkurrencefordel ifht konkurrenterne

[forsent]

Halløjsa, jeg kan se at på Genmabs hjemmeside er der endelig kommet noget med fra deres samarbejde med Lundbeck. Fase I mod parkinson :D. Har de ikke også et samarbejde med Novo?

[forsent]

Altså ikke at det betyder noget som helst for kursen før om mange år, men for langsigtede er det alligevel rart at se nye og andre ting end kræft-forsøg synes jeg

[bikube]

forsent - Genmab har lige modtaget første milestone betaling fra Novo, så det kører.

[forsent]

ok super, mange tak for svar

[Plimsoller]

God morgen

[transalp]

Go morgen

[bibob]

God morgen.

[henrik48]

God morgen

[polle1]

God morgen

[Parasitism]

God morgen

[E_L]

God morgen

[E_L]

Sequencing Through Multiple Lines of Therapy https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/sequencing-through-multiple-lines-of-therapy

[E_L]

Daratumumab in Primary Effusion Lymphoma
https://www.nejm.org/doi/full/10.1056/NEJMc1806295

[E_L]

Is immunotherapy cost-effective? http://www.oncologytube.com/video/is-immunotherapy-cost-effective/10004937

[Bulder]

Thx again E L for your vigorous research. Dara is establishing itself as soc after 1. relapse. Soon it will move up front.

[bibob]

Thx E L and Bulder. Sounds promising.

[Sukkeralf]

Thanks - somebody knows what the problem mentioned with BCMA is?

[Sukkeralf]

So, if somebody is not lenalidomide sensitive, there is really no on-label use of elotuzumab right now. I’m sure we’re going to get to this more, but the BCMA is now becoming an issue as well.

[gentogen]

Ved det ikke, men fandt dette: "a main concern, which is the possibility of CAR T–BCMA–induced immune editing whereby residual MM cells decrease their BCMA expression following CAR T cell infusion, enabling immune evasion. Therefore, using a dual- or even triple-targeting CAR could potentially overcome this problem and enhance the response rate to CAR T cell therapy"